Keros Therapeutics’ (KROS) Overweight Rating Reiterated at Cantor Fitzgerald

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday,Benzinga reports.

KROS has been the topic of several other reports. Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target for the company. Jefferies Financial Group assumed coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Guggenheim began coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $54.28 on Friday. The company has a market capitalization of $2.20 billion, a PE ratio of -10.35 and a beta of 1.23. Keros Therapeutics has a 52-week low of $27.31 and a 52-week high of $73.00. The business’s fifty day moving average is $59.33 and its 200 day moving average is $52.29.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm’s revenue was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.33) EPS. On average, sell-side analysts forecast that Keros Therapeutics will post -5.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in KROS. Vanguard Group Inc. raised its holdings in Keros Therapeutics by 7.9% in the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock worth $102,329,000 after purchasing an additional 113,563 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares during the period. American International Group Inc. increased its stake in shares of Keros Therapeutics by 13.1% in the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after acquiring an additional 1,465 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Keros Therapeutics by 117.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock valued at $345,000 after acquiring an additional 2,822 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Keros Therapeutics by 17.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after acquiring an additional 176,803 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.